Gilead Sciences, Inc. vs Plug Power Inc — how do they compare? Gilead Sciences, Inc. trades at $136.16 (market cap $164.99B), while Plug Power Inc trades at $2.24 (market cap $2.94B). The key difference: Gilead Sciences, Inc. is far larger — about 56.1× Plug Power Inc's market cap, and Gilead Sciences, Inc. pays a 2.47% dividend while Plug Power Inc pays none. Which is the better fit depends on your goals.
| GILD | PLUG | |
|---|---|---|
Market Cap | $164.99B | $2.94B |
Sector | Health | Industrials |
52-Week High | $155.80 | $4.14 |
52-Week Low | $110.56 | $1.41 |
Enterprise Value | $188.06B | $3.73B |
Dividend Yield | 2.47% | — |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.21, up 1.8% in the last session, with a bullish technical outlook and strong analyst support. Recent Q2 2026 results showed a revenue beat despite a net loss driven by acquisition costs, with HIV drug sales and pipeline progress fueling raised full-year guidance. The stock exhibits robust cash flow from operations and a high gross margin, though negative net income and elevated debt levels present fundamental concerns.
The outlook is positive based on raised sales guidance and pipeline momentum, but risks include patent cliffs for key HIV drugs by the mid-2030s and integration challenges from recent acquisitions. With a consensus price target of $151.22 implying 13.5% upside, Wall Street sentiment is bullish, though investors should weigh growth prospects against execution and regulatory risks.
Plug Power (PLUG) trades at $2.18, up 5.31% with a bearish technical signal despite recent earnings beat. The company shows improving operational metrics with reduced cash usage and margin improvements, though it remains unprofitable with negative gross margins of -25.66%. Management targets positive EBITDA by Q4 2026 while navigating significant liquidity challenges through asset sales and financing activities.
While analyst consensus leans bullish with a $2.22 price target, PLUG faces substantial execution risks amid persistent losses and cash burn. The stock offers speculative upside if management delivers on profitability targets, but investors face elevated risk from the company's negative cash flow and competitive hydrogen market pressures.
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →